investors.xencor.com/static-files/...3-4dea-9ec8-6aff9841b281
"
The U.S. FDA approved Monjuvi (tafasitamab-cxix), the second product with XmAb technology to be approved for commercial marketing, in July 2020. Monjuvi is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of certain adult patients with relapsed or refractory DLBCL, and it was created and initially developed by us. Monjuvi is co-commercialized in the U.S. by MorphoSys and Incyte. The European Marketing Authorization Application for tafasitamab is currently under review by the European Medicines Agency. In 2020, we earned a total of $37.5 million in regulatory milestones and royalties of $1.5 million on net sales of Monjuvi.
"
www.fiercepharma.com/marketing/...n-line-morphosys-ceo-touts-
monjuvi-s-potential-but-covid-19-slows
"
Monjuvi brought in sales of €18.5 million ($22 million) in 2020 after earning its FDA nod in August, largely in line with industry watchers’ expectations. For 2021, the company’s projecting total revenues of €150 million to €200 million.
"
wäre auf jeden Falls spannend zu wissen, ob sich MOR das mit Incyte shared oder aus einem Anteil zahlen muss.
"
The U.S. FDA approved Monjuvi (tafasitamab-cxix), the second product with XmAb technology to be approved for commercial marketing, in July 2020. Monjuvi is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of certain adult patients with relapsed or refractory DLBCL, and it was created and initially developed by us. Monjuvi is co-commercialized in the U.S. by MorphoSys and Incyte. The European Marketing Authorization Application for tafasitamab is currently under review by the European Medicines Agency. In 2020, we earned a total of $37.5 million in regulatory milestones and royalties of $1.5 million on net sales of Monjuvi.
"
www.fiercepharma.com/marketing/...n-line-morphosys-ceo-touts-
monjuvi-s-potential-but-covid-19-slows
"
Monjuvi brought in sales of €18.5 million ($22 million) in 2020 after earning its FDA nod in August, largely in line with industry watchers’ expectations. For 2021, the company’s projecting total revenues of €150 million to €200 million.
"
wäre auf jeden Falls spannend zu wissen, ob sich MOR das mit Incyte shared oder aus einem Anteil zahlen muss.